10096534An innovative medical device that helps to manage haemorrhage in definitive care that could save 16,000 lives/year in the UKClosedInvestment AcceleratorInnovate UKI decided to found ACT medical after two of my friends were stabbed on the streets of London. ACT Medical is a UK-based medical device SME looking to revolutionise the treatment of catastrophic haemorrhage. Globally, over 1.4 million deaths occur in definitive care each year due to catastrophic haemorrhage. With 4000 major complications occurring every hour, speed of treatment is essential. Reducing operative blood loss improves patient outcomes and reduces healthcare costs - each transfused RBC unit costs up to £900\. Current solutions are to apply pressure to the bleed site, use packing if necessary, before repairing the affected artery or vein. Tools such as fibrin glues and haemostatic agents are available to assist in stemming bleeding. However, current solutions can take up to three hours to remove and blood clots are destabilised on removal. Existing solutions also require additional manual pressure which ties up a member of the operating team. This can delay surgeries, and in some instances can cancel them entirely. ACT has recognised this problem and is looking to leverage its IP for the treatment of intraoperative bleeding. The solution will look to address the user needs highlighted in this projects' user interviews and will provide benefits such as hands-free pressure application and ease of removal. ACT's solution will improve haemorrhage control for intraoperative bleeding and has the potential to save 16,000 UK lives annually, and a corresponding £1.6bn.